Tenor Capital Management »

Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Tenor Capital Management

Quarter-by-quarter ownership of Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Tenor Capital Management from 13F filings

Historical chart of Tenor Capital Management investment in Sarepta Therapeutics Inc Note 1.250 9/1

Tip: Access up to 7 years of quarterly data

All positions including Sarepta Therapeutics Inc Note 1.250 9/1 held by Tenor Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sarepta Therapeutics Inc Note 1.250 9/1 by Tenor Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $39B 39M 1015.75
2023-09-30 $39B 35M 1121.96

More positions owned by Tenor Capital Management

Palo Alto Networks Note 0.375% 6/0 (Principal)
Insight Enterprises Note 0.750% 2/1 (Principal)
Ziff Davis Note 1.750%11/0 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Block Note 0.125% 3/0 (Principal)
Zscaler Note 0.125% 7/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Alteryx Note 0.500% 8/0 (Principal)
Five9 Note 0.500% 6/0 (Principal)
Mongodb Note 0.250% 1/1 (Principal)
Liberty Media Corp Note 2.750% 12/0 (Principal)
United States Stl Corp Note 5.000%11/0 (Principal)
Ati Note 3.500% 6/1 (Principal)
Evolent Health Note 1.500%10/1 (Principal)
Hubspot Note 0.375% 6/0 (Principal)

View all positions for Tenor Capital Management

Top funds holding Sarepta Therapeutics Inc Note 1.250 9/1

Wolverine Asset Management
Calamos Advisors
Braidwell
Highbridge Capital Management
Davidson Kempner Capital Management
Readystate Asset Management
Bank of America Corporation
Lazard Asset Management
Tenor Capital Management
D. E. Shaw & Co
Bank Of Montreal
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Steelhead Partners
Context Capital Management
Capstone Investment Advisors

View all funds holding Sarepta Therapeutics Inc Note 1.250 9/1